Excalipoint: Bringing co-stimulation, masking and more to solid tumor T cell engagers

Excalipoint Therapeutics is betting it can do two hard things at once in solid tumor T cell engagers: move quickly and address several of the modality’s key limitations in parallel.

Founded in August 2025 around in-licensed assets and a team that includes former Lepu Biopharma Co. Ltd. (HKEX:2157) executives and scientists, the Shanghai-based biotech already has three trispecific T cell engager platforms and six programs, including one in the clinic...